focus -WSS

focus

author：hotspot 2025-10-01 14:40:28 - browse：457

3D dollar signs come out of a prescription drug bottle — coverage from STAT — Adobe

WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s new power to negotiate drug prices, according to Congress’ nonpartisan budget experts.

The Inflation Reduction Act includes two measures that directly lower drug prices. Medicare price negotiation is the most controversial of the two. The law gives drugs 9 years on the market before negotiated prices take effect; biologics get 13 years. Drugs are selected for negotiation among the 50 top-selling drugs without generic or biosimilar competition. Medicare will negotiate prices for 10 drugs to start. Up to 60 drugs will be subject to negotiation over the next four years, and up to 20 more drugs every year afterward.

The law also requires drug companies to pay back Medicare when they raise prices on drugs faster than inflation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Study: Spinal cord stimulation helps patients with paralysis walk again

Wikipedia

WSS

How to make over

Hospital at home shows how to bring innovation to health care

Roivant's CEO is a star, but biotech's black hole persists

Former Pear Therapeutics executives start new VC firm

Study: Spinal cord stimulation helps patients with paralysis walk again

Roche acquires Telavant from Roivant, adding experimental IBD treatment

hotspot

focus

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Intellia plays down concerns on accidental germline transmission

At least 13 dead in Texas as scorching temps continue

J&J lung cancer data amount to new salvo against AstraZeneca

Tori Bowie and the unacceptable rates of Black maternal death

Wegovy improves function in certain heart failure patients

DIEP, the 'gold standard' of breast reconstruction, is under threat

Roche drug slashes death risk in early

The cancer drug shortage isn’t new — and neither are the solutions

Smaller biotechs seek to piggyback on weight loss drug boom

hotspot

FDA advisory panel to debate high blood pressure devices

Study: Spinal cord stimulation helps patients with paralysis walk again

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Results on Novartis prostate cancer therapy could expand its use

Readout LOUD podcast: Live from the 2023 STAT Summit

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Wikipedia

Wikipedia

focus

hotspot